Ian Krop

Oncology · 2011–2019

A researcher in the Science corpus: 9 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Ian Krop trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Pardoll (in Oncology)

Papers from Ian Krop's perspective

Ordered by how strongly the researchers Ian Krop trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
  2. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer… (Journal of the National Cancer Institute)
  3. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  4. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  5. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial (The Lancet)
  6. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. (Journal of Clinical Oncology)
  7. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. (Cancer Research)
  8. Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis (Journal of immunotherapy)
  9. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. (The Lancet Oncology)
  10. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)

Their papers